Ahmed Koriesh on Comparison of Apixaban and Warfarin
Ahmed Koriesh, Director Hospital Neurology Service at Cleveland Clinic Florida, shared on LinkedIn:
”How many patients have you seen with stroke or bleeding related to warfarin in LVAD patients?
A recent trial in LVAD patients compared apixaban with warfarin over 2 years:
Lower HRAEs (stroke, bleeding, thrombosis):
12.5% vs 43% (p=0.087)
Significantly fewer transfusions:
0.69 vs 4.82 EPPY (p<0.01)
Win ratio favored apixaban:
2.30 (95% CI 0.95–5.60)
Although underpowered, the signals consistently leaned toward apixaban with no excess thrombosis or mortality observed.
Bottom line:
Apixaban is showing a promise as a safe alternative to warfarin in selected LVAD patients — larger trials are needed before changing practice.”
Stay updated with Hemostasis Today.
-
Aug 21, 2026, 21:58Toby Richards: WEHI Trial Solidifies IV Iron as Third-Trimester Standard
-
Aug 21, 2026, 21:51Mehak Trehan: From Reading the Chapter to Writing One
-
Aug 21, 2026, 21:38Ann Reilly: Navigating Postoperative vs. Acute Blood Loss Anemia – A CDI Case Study
-
Aug 21, 2026, 21:29Merlin Crossley: Atomic Precision in Sickle Cell Care – Structural Targeting for Fetal Globin Reactivation
-
Aug 21, 2026, 19:09Aphisit Thongthaisin: Admitted to Sorbonne University’s T2H University Diploma for 2026/2027
-
Aug 21, 2026, 19:07José Luis Ferreiro Gutiérrez: Proud to Be Elected Chairperson-Elect of the ESC Working Group on Thrombosis
-
Aug 21, 2026, 19:00Manuel Monreal: New RIETE Registry Data on VTE Recurrence and Bleeding During Anticoagulation
-
Aug 21, 2026, 18:39Ronak H. Mistry: Updated ASH ITP Guidelines Bring New Guidance for Managing ITP
-
Aug 21, 2026, 18:22Ahmed Bennis: NOAC Use Is Associated With Slower Cognitive Decline in AF and Alzheimer’s Disease